Remove 2003 Remove Biopharma Remove Pharma
article thumbnail

Ten Ways to Think Differently About Small-to-Mid-Sized Pharma Launches

Eversana Intouch

Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. Yet, we know small-to-mid-sized pharma launches face a unique set of challenges.

Pharma 105
article thumbnail

The Biotech Effect

Pharmaceutical Technology

“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. ”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How VMS BioMarketing Accelerated Digital Transformation with Silverline

Silver Line CRM

VMS biopharma clients expect them to move quickly — and to do so, the company saw an opportunity to streamline processes, drive efficiencies, and make it more seamless for its team to work together. . Our custom system was built in 2003,” said Brochhagen.

article thumbnail

Navigating one’s career journey to the CEO role: An MIT Sloan Career Development Office Q&A with Warburg Pincus’ Fred Hassan

PM360

It was interesting to see how the peer CEOs at the time of your published book Reinvent , not only from the biopharma sector but also fromCPG, chemicals, and many other verticals. Mr. Hassans public boards include Precigen, EyePoint, Cocrystal Pharma, and BridgeBio.

article thumbnail

How the U.S. election could impact the healthcare industries

Clarivate

Since the government first created a Part D benefit with the Medicare Modernization Act of 2003 (MMA) , Democrats have agitated for greater governmental input into the cost of prescription drugs for Medicare beneficiaries.